AstraZeneca
Article Abstract:
AstraZeneca is subject to an investigation by the competition authorities of the European Union, and the company may be fined, though fears regarding this raid appear to be exaggerated. The performance of Nexium to follow up Losec, has yet to be assessed.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
AstraZeneca
Article Abstract:
AstraZeneca faces the expiry of its Losec ulcer drug, and needs replacements to strengthen sales. The company has a number of new drugs at late-stage, such as Crestor.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
AstraZeneca
Article Abstract:
AstraZeneca faces the loss of Losec patents, though the company has other promising products.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Granada
- Abstracts: Railtrack
- Abstracts: Standard Chartered
- Abstracts: Analysis of vertebrate SCL loci identifies conserved enhancers. Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin
- Abstracts: Alliance and Leicester